Clinical trials
CAR T Cell clinical trials
Below are recruiting car t cell clinical trials, each written for real people, not researchers. We’re tracking 643 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05620680Recruiting
CD7 CAR-T for relapsed or resistant T-cell cancers
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
Shenzhen, GuangdongAges 18–75 - NCT05779917RecruitingPhase 1
CAR-T cells for cancers that have specific target proteins
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
Guangzhou, GuangdongAges 18–75 - NCT06439173Recruiting
Study on bone marrow recovery after CAR-T therapy
This study is looking at why some people develop low blood cell counts after CAR-T therapy for a type of lymphoma. It aims to find ways to help the bone marrow recover and work better.
SalamancaAges 18 years+ - NCT06014073RecruitingPhase 1/Phase 2
A new CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a special type of CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to standard treatments. The CAR-T cells are made from a donor and have genes removed to work better. The goal is to see if this treatment is safe and effective.
BeijingAges 18–70 - NCT06871410RecruitingPhase 1
Engineered immune cells for relapsed or refractory AML
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
Buffalo, New YorkAges 18 years+ - NCT06768905RecruitingPhase 1/Phase 2
Radiation followed by CAR-T cells for relapsed/refractory DLBCL
This trial tests a new two-step treatment: first a small dose of radiation (131I-Apamistamab) followed by specially designed immune cells (CAR-T cells) to fight your lymphoma. It is for people with DLBCL that has relapsed or not responded to standard therapy.
Dallas, TexasAges 18 years+ - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT07116057RecruitingPhase 1
CAR T cell therapy for FRa-positive cancers
This trial tests a new treatment called MOv19-BBz CAR T cells, which are specially designed immune cells that target a protein called FRa found on some cancer cells. It's for people with advanced lung cancer that has spread to the lining of the lung (malignant pleural effusion) and who have already tried at least one standard treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06026319RecruitingPhase 1
Immune cells for lymphoma that has returned
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
Boston, MassachusettsAges 18 years+ - NCT06642025RecruitingEarly Phase 1
EX02 car-t cells for hard-to-treat acute myeloid leukemia
This trial tests a new treatment called EX02 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses your own immune cells, modified to target a specific marker on leukemia cells, to help fight the cancer.
Hefei, AnhuiAges 18–70 - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07855302RecruitingPhase 1
CAR T-cell therapy for young people with lupus
This trial tests a treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. It is for young people whose lupus is active despite trying several standard treatments.
SeoulAges Up to 25 years - NCT05757219RecruitingPhase 2
Itacitinib before CAR T for aggressive B-cell lymphoma
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
Tampa, FloridaAges 18 years+ - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT06793241RecruitingEarly Phase 1
Donor CAR-T cells for B-cell leukemia
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
Hangzhou, ZhejiangAges 18 years+ - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06346912RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell blood cancers
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT06904729RecruitingPhase 3
CAR-T cell therapy for tough lupus kidney disease in children
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
Guangzhou, GuangdongAges 6–18 - NCT06318533RecruitingEarly Phase 1
Engineered immune cell therapy for autoimmune diseases
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
Zhenjiang, JiangsuAges 18–70 - NCT06735495RecruitingPhase 1/Phase 2
Two-target CAR T cells for relapsed B-cell blood cancers
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
Wuhan, HubeiAges 3–75 - NCT07369492RecruitingPhase 1
Study of BAFF-R CAR-T cells for CD19-negative B-cell lymphoma
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
SuzhouAges 18 years+ - NCT06716164RecruitingEarly Phase 1
Experimental car-t cell therapy for relapsed b-cell lymphoma
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hangzhou, ZhejiangAges 19–70 - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70
Hear when a new CAR T Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car t cell?
- Yes. Clin2 currently lists 643 recruiting car t cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car t cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car t cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.